Genentech eye implant to improve delivery of Lucentis may improve sales, too
This article was originally published in Scrip
Genentech is developing an intraocular implant for the delivery of its age-related macular degeneration (AMD) drug Lucentis (ranibizumab) over a longer period, thereby reducing the dosing frequency. Although Genentech has not discussed the strategy behind the move, it is possible that migrating patients onto the device-delivered form of Lucentis could not only be a useful part of life-cycle management for the drug, but might also encourage patients to seek Lucentis, rather than the similar but much cheaper vascular endothelial growth factor inhibitor, Avastin, another Genentech product.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.